Vicore Pharma AB

Address: Kornhamnstorg 53

Sponsor Overview

assignment

Specializations

Idiopathic pulmonary fibrosis

Vicore Pharma AB concentrates its clinical research on idiopathic pulmonary fibrosis, with studies centered on disease progression, respiratory function, and treatment effects in affected participants.

Forced vital capacity
Lung fibrosis
Respiratory impairment

The sponsor’s work in this area is directed toward understanding therapeutic impact on pulmonary function in a chronic fibrotic lung disease.

Oral small-molecule therapy

Its research portfolio includes clinical evaluation of an oral small-molecule treatment candidate, with attention to formulation, safety, and pharmacokinetic behavior in human participants.

Buloxibutid
Oral formulations
Pharmacokinetics

This area reflects interest in treatments designed for systemic administration and long-term use in fibrotic lung disease.

Drug metabolism and interaction science

Vicore Pharma AB also studies how its candidate therapies behave in the presence of metabolic pathway modulation, with a focus on drug-drug interactions and enzyme-related exposure changes.

CES2 inhibition
CYP3A4 inhibition
Metabolic profiling

These investigations support interest in hepatic metabolism and the clinical handling of orally administered agents.

Safety and tolerability assessment

The sponsor’s trials include evaluation of safety and tolerability in healthy volunteers and patients, with emphasis on human exposure and treatment acceptability.

Healthy volunteers
Adverse event monitoring
Clinical safety

This area supports the development of therapies intended for use in chronic respiratory disease.

Trial Name	Country	Status
Effect of Carboxylesterase 2 and CYP3A4 Inhibition on the Pharmacokinetics of Buloxibutid in Healthy Volunteers: A Randomized Open-Label Drug-Drug Interaction Study	Sweden	Recruiting
Efficacy and Safety Evaluation of Buloxibutid in Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial	Austria Belgium Germany Greece Italy Poland	Not Recruiting
Pharmacokinetics and Safety Assessment of Buloxibutid (C21) Oral Formulations in Idiopathic Pulmonary Fibrosis: A Randomized, Open-Label, Cross-Over Study	Sweden	Not Recruiting